Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

November 11, 2021

Study Completion Date

April 12, 2023

Conditions
Hypoglycemia, ReactiveHypoglycemia
Interventions
DEVICE

Dexcom CGM masked

"The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."

DEVICE

Dexcom CGM unmasked

"During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."

Trial Locations (1)

02215

Joslin Diabetes Center, Boston

All Listed Sponsors
collaborator

DexCom, Inc.

INDUSTRY

lead

Joslin Diabetes Center

OTHER

NCT03353415 - Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery | Biotech Hunter | Biotech Hunter